Companies › Brii Biosciences
3 active drug programs in 10 registered trials: 9 Phase 2, 1 Phase 4; Infectious disease; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BRII-179 HBV therapeutic vaccine (T-cell activating immunotherapy) | – | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection | Sep 2028 |
| BRII-835 (VIR-2218, elebsiran) | – | Phase 2 | Chronic Hepatitis B Virus Infection; For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection | Sep 2028 |
| Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis B | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05970289 | BRII-835 (VIR-2218, elebsiran) | Phase 2 | Chronic Hepatitis B Virus Infection | Infectious disease | Jul 2025 |
| NCT06491563 | BRII-179 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | Infectious disease | Aug 2026 |
| NCT06491563 | BRII-835 (VIR-2218, elebsiran) | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | Infectious disease | Aug 2026 |
| NCT06491563 | Peginterferon Alfa-2A | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | Infectious disease | Aug 2026 |
| NCT07573943 | Peginterferon Alfa-2A | Phase 4 | Chronic Hepatitis b | Infectious disease | Dec 2026 |
| NCT05771402 | Peginterferon Alfa-2A | Phase 2 | Chronic Hepatitis b | Infectious disease | Dec 2026 |
| NCT07845058 | Peginterferon Alfa-2A | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT06650852 | BRII-179 | Phase 2 | Chronic Hepatitis B Virus (HBV) Infection | Infectious disease | Sep 2028 |
| NCT06650852 | BRII-835 (VIR-2218, elebsiran) | Phase 2 | Chronic Hepatitis B Virus (HBV) Infection | Infectious disease | Sep 2028 |
| NCT06650852 | Peginterferon Alfa-2A | Phase 2 | Chronic Hepatitis B Virus (HBV) Infection | Infectious disease | Sep 2028 |
Diakonos Oncology PharmaEssentia BriaCell Therapeutics Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical
CastleVax Medicago Eveliqure Biotechnologies Sanaria SIGA Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.